This is going to be a huge story.
| |
Dear Reader,
Next week, we're doing something unprecedented.
We're hosting our first-ever live Cancer Briefing.
Now, if you're like most folks, you probably hate even thinking about cancer.
But I can guarantee you don't want to miss what my colleagues, Dave Lashmet and Dr. David "Doc" Eifrig, are putting together for you.
You see, I've always felt the best way we could help you was by showing you how to make money with investment ideas.
But when I saw what Dave and Doc are preparing for next week, I realized there's an entire world of research we've never shared with you… until now.
During the live event, Dave and Doc will tell you about a radical new cancer treatment that could help as many as 800,000 Americans per year. Even better, you could make up to 5 times your money on the little-known company behind it.
This is going to be a huge story.
It's going to change cancer medicine forever.
To our knowledge, we are the first in our industry to write about it.
Next week, we'll show you not only how to destroy any cancer you or someone you love may one day face… but how to make a fortune on the company behind it all.
As Porter Stansberry says, "This will be a must-see event for anyone who's had cancer… or been touched by cancer."
To register for the event, click here.
Regards,
Justin Brill
Editor, The Stansberry Digest |
|
| |
All contents of this e-mail are copyright 2017 by Stansberry Research. All rights reserved. Reproducing any part of this document is prohibited without the express written consent of Porter Stansberry. Protected by U.S. Copyright Law {Title 17 U.S.C. Section 101 et seq., Title 18 U.S.C. Section 2319}: Infringements can be punishable by up to five years in prison and $250,000 in fines.
DISCLAIMER: The work included in this publication is based on SEC filings, current events, interviews, and corporate press releases. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. The views expressed in this publication do not necessarily reflect the views of Stansberry Research.
You're receiving this email at [email protected]. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday-Friday between 9:00 a.m. and 5:00 p.m. Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles Street Baltimore, MD 21201. If you wish to contact us by email, please do not reply to this message but instead go to [email protected].
To unsubscribe from this mailing, click here: Unsubscribe
|
|
|
